Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

WSJ • 10 hours ago

Amgen says CFO Peter Griffith to retire, names Dittrich as successor

Amgen said on Tuesday its chief financial ​officer, Peter Griffith, would retire, with ‌Thomas Dittrich taking over the role in September.

Reuters • May 19, 2026

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020.

PRNewsWire • May 19, 2026

Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports

At least ​20 people ‌in Japan who ​took ​Amgen's rare disease ⁠drug ​have died, ​while 22 others developed ​potentially ​fatal liver injuries, ‌the ⁠Wall Street Journal reported ​on ​Friday, ⁠citing partner ​Kissei ​Pharmaceutical.

Reuters • May 15, 2026

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • May 15, 2026

Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug.

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

WSJ • May 15, 2026

Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

New Study Finds These Sectors Produce the Most 100-Bagger Stocks

On a recent episode of The Compound and Friends, hosts Josh Brown and Michael Batnick sat down with former Janus analyst Matt Ancrum to discuss his study of 100-bagger stocks.

24/7 Wall Street • May 12, 2026

2 Dividend Stocks to Double Up On Right Now

Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.

The Motley Fool • May 8, 2026

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.

PRNewsWire • May 7, 2026